Version October 2024
Note: Potency varies among currently available products; use caution to ensure correct dose is administered.
Postexposure prophylaxis (ACIP Recommendation): Local wound infiltration: 20 units/kg single dose administered as soon as possible after exposure. If anatomically feasible, the full rabies immune globulin (RIG) dose should be infiltrated around and into the wound(s); any remaining volume should be administered IM at a site distant from the vaccine administration site. If rabies vaccine was initiated without rabies immune globulin, rabies immune globulin may be administered through the seventh day after the first vaccine dose. Administration of RIG is not recommended after the seventh day postvaccine since an antibody response to the vaccine is expected during this time period (Ref).
Note: Not recommended for use in persons with a history of vaccination (preexposure or postexposure) and documentation of antibody response. Potency varies among currently available products; use caution to ensure correct dose is administered.
Postexposure prophylaxis: Infants, Children, and Adolescents: Local wound infiltration/IM: 20 units/kg single dose administered as soon as possible after exposure and as part of a rabies vaccine regimen; do not exceed recommended dose since passive antibody can interfere with response to rabies vaccine. If anatomically feasible, the full rabies immune globulin (RIG) dose should be infiltrated around and into the wound(s); any remaining volume should be administered IM at a site distant from the vaccine administration site. If rabies vaccine was initiated without rabies immune globulin, rabies immune globulin may be administered through the seventh day after the first vaccine dose. Administration of RIG is not recommended after the seventh day postvaccine since an antibody response to the vaccine is expected during this time period.
There are no dosage adjustments provided in manufacturer's labeling.
There are no dosage adjustments provided in manufacturer's labeling.
(For additional information see "Rabies immune globulin (human): Drug information")
Note: Potency varies among currently available products; use caution to ensure correct dose is administered.
Rabies, postexposure prophylaxis: Local wound infiltration/IM: 20 units/kg in a single dose, rabies immune globulin (human) (HRIG) should always be administered as part of rabies vaccine regimen. If anatomically feasible, the full rabies immune globulin dose should be infiltrated around and into the wound(s); remaining volume should be administered IM at a site distant from the vaccine administration site. HRIG should be administered as soon as possible after exposure, preferably at time of first rabies vaccine dose. If rabies vaccine was initiated without HRIG, HRIG may be administered through the seventh day after the administration of the first dose of the vaccine (day 0). Administration of HRIG is not recommended after the seventh day post vaccine since an antibody response to the vaccine is expected during this time period.
Note: Not recommended for use in persons with a history of complete rabies vaccination (preexposure or postexposure prophylaxis) and documentation of antibody response.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%:
Central nervous system: Headache (8% to 15%)
Local: Pain at injection site (31% to 33%)
1% to 10%:
Central nervous system: Fatigue (2% to 6%), dizziness (1% to 6%)
Dermatologic: Sunburn (≤3%)
Gastrointestinal: Diarrhea (8%), flatulence (8%), nausea (4%), abdominal pain (1% to 4%)
Genitourinary: Leukocyturia (3% to 5%), hematuria (2% to 4%)
Hematologic & oncologic: Bruise (1% to 3%)
Local: Injection site nodule (8%)
Neuromuscular & skeletal: Myalgia (7% to 9%), arthralgia (≤6%)
Respiratory: Upper respiratory tract infection (9% to 10%), nasal congestion (8%), oropharyngeal pain (8%)
Frequency not defined:
Central nervous system: Malaise
Dermatologic: Skin rash
Genitourinary: Nephrotic syndrome
Hypersensitivity: Anaphylaxis, angioedema
Local: Local soreness/soreness at injection site, tenderness at injection site
Neuromuscular & skeletal: Stiffness (at injection site)
Miscellaneous: Fever (mild)
<1%, postmarketing, and/or case reports: Hypersensitivity reaction, hypoesthesia, limb pain
Imogam Rabies-HT: Should not be administered in repeated doses once vaccine treatment has been initiated (may interfere with active immunity of vaccine).
HyperRAB, Kedrab: There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions can occur; discontinue immediately and institute supportive emergency measures if hypersensitivity or anaphylaxis occurs. Use with caution in patients with isolated immunoglobulin A deficiency or a history of systemic hypersensitivity to human immunoglobulins. Medications for the treatment of acute allergic reactions should be available for immediate use.
• Hemolysis: May occur; risk is increased in patients with non-O blood group types, underlying associated inflammatory conditions, and those receiving high cumulative doses of immune globulins over several days. Monitor patients for signs and symptoms of hemolysis (eg, fever, chills, dark urine).
• Thrombosis: Use with caution in patients at increased risk of thrombosis (eg, acquired or hereditary hypercoagulable states, prolonged immobilization, indwelling vascular catheters, advanced age, estrogen use, history of thrombosis, cardiovascular risk factors, hyperviscosity syndromes). Monitor these patients for at least 24 hours after administration; consider measuring a baseline blood viscosity in patients at risk for hyperviscosity.
Disease-related concerns:
• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from IM administration.
Dosage form specific issues:
• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease agent and, theoretically, the Creutzfeldt-Jakob disease agent), which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.
Other warnings/precautions:
• Administration: Not for intravenous administration.
• Administration: Administration is a medical urgency (not emergency); however, do not delay decision to treat.
• Appropriate use: A single dose is recommended; repeating the dose may interfere with maximum active immunity expected from the vaccine. Repeated doses of Imogam Rabies-HT after vaccine treatment has been initiated are contraindicated.
• Immunizations: Antibodies may interfere with the immune response to live vaccines. Live vaccines should be given ≥3 months after rabies immune globulin (defer live vaccines ≥4 months after HyperRAB); measles vaccine should be given ≥4 months after Kedrab.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Injection:
Imogam Rabies-HT: 300 units/2 mL (2 mL)
Solution, Injection [preservative free]:
HyperRAB: 300 units/mL (1 mL); 900 units/3 mL (3 mL); 1500 units/5 mL (5 mL)
HyperRAB S/D: 300 units/2 mL (2 mL [DSC]); 1500 units/10 mL (10 mL [DSC])
Kedrab: 300 units/2 mL (2 mL); 1500 units/10 mL (10 mL) [latex free, pyrogen free]
Yes
Solution (HyperRAB Injection)
300 units/mL (per mL): $816.60
900UNIT/3ML (per mL): $816.60
1500 unit/5 mL (per mL): $816.59
Solution (Imogam Rabies-HT Injection)
300 units/2 mL (per mL): $543.08
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injectable, Intramuscular:
HyperRAB S/D: 150 units/mL ([DSC])
Generic: 150 units/mL ([DSC])
Solution, Injection:
HyperRAB: 300 units/mL (1 mL, 5 mL)
Kamrab: 300 units/2 mL (2 mL)
Parenteral: Postexposure wound infiltration: Thoroughly cleanse wound(s) with soap and water; irrigate wounds with viricidal agent (eg, povidone-iodine) if available. If anatomically feasible, the full rabies immune globulin (RIG) dose should be infiltrated around and into the wound(s); remaining volume should be administered IM in the deltoid muscle of the upper arm or lateral thigh muscle at a site distant from rabies vaccine administration. Per the manufacturer, the gluteal area should be avoided to reduce the risk of sciatic nerve damage or unpredictable absorbance (unless exposure area is the gluteal area). Do not administer IV. If IM administration is contraindicated (eg, patients with uncorrectable bleeding disorders), Kedrab may be administered SubQ; however, no clinical efficacy data are available to support administration SubQ. Do not administer rabies vaccine in the same syringe or at the same administration site as RIG. For extensive wounds, do not exceed the calculated dose. For extensive wounds, do not exceed the calculated dose. If the location of the wound is unknown or if infiltration is difficult at the bite site (eg, lips, fingers, knee), administer the full dose at a site distant from the site of the rabies vaccination. If additional volume is needed to infiltrate the wound(s), may dilute with an equal volume of D5W (HyperRAB) or NS (Kedrab, Imogam) (Ref); HyperRAB should not be diluted with NS. If a large intramuscular volume is required (>2 mL for children or >5 mL for adults), administer the total volume in divided doses at different sites.
IM: Postexposure wound infiltration: For wound infiltration and IM use only; do not administer IV. Clean wounds immediately with soap and water; irrigate wounds with viricidal agent (eg, povidone-iodine) if available. If anatomically feasible, the full rabies immune globulin (human) (HRIG) dose should be infiltrated around and into the wound(s); remaining volume should be administered IM in the deltoid muscle of the upper arm or lateral thigh muscle. Per the manufacturer, the gluteal area should be avoided to reduce the risk of sciatic nerve damage or unpredictable absorbance, unless gluteal region is exposure site. Do not administer rabies vaccine in the same syringe or at the same administration site as HRIG. For extensive wounds, do not exceed the calculated dose. If the location of the wound is unknown or if infiltration is difficult at the bite site (eg, lips, fingers, knee), administer the full dose at a site distant from the site of the rabies vaccination. If additional volume is needed to infiltrate the wound(s), may dilute with an equal volume of D5W (HyperRAB) or NS (Kedrab, Imogam) (Ref); HyperRAB should not be diluted with NS.
Store between 2°C to 8°C (36°F to 46°F); do not freeze. Discard unused portion immediately and any product exposed to freezing. HyperRAB may be stored at room temperature (≤25°C [≤77°F]) for up to 6 months; do not return to refrigeration. Kedrab may be stored at room temperature (≤25°C [≤77°F]) for up to 1 month; do not return to refrigeration. Extended storage information at room temperature for other products may be available; contact product manufacturer to obtain current recommendations.
Part of postexposure prophylaxis of persons with suspected rabies exposure. Provides passive immunity until active immunity with rabies vaccine is established (FDA approved in all patients). Not for use in persons with a history of vaccination (preexposure or postexposure) and documentation of antibody response. Each exposure to possible rabies infection should be individually evaluated.
Factors to consider include: Species of biting animal, circumstances of biting incident (provoked vs unprovoked bite), type of exposure to rabies infection (bite vs nonbite), vaccination status of biting animal, and presence of rabies in the region. See product information for additional details.
Bayrab [Philippines, Turkey] may be confused with Bayhep-B which is a brand name for hepatitis B immune globulin [Philippines, Turkey]; Bayrho-D which is brand name for RhoD immune globulin [Israel, Turkey]
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
Dinutuximab Beta: Immune Globulins may diminish the therapeutic effect of Dinutuximab Beta. Risk X: Avoid combination
Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy
Rabies Vaccine: Rabies Immune Globulin (Human) may diminish the therapeutic effect of Rabies Vaccine. Management: Do not administer additional or repeated doses of rabies immune globulin once rabies vaccine has been administered. The rabies immune globulin should also not be administered in the same site as the vaccine. Risk D: Consider therapy modification
Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents. Risk C: Monitor therapy
Vaccines (Live): Rabies Immune Globulin (Human) may diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin. Risk D: Consider therapy modification
Animal reproduction studies have not been conducted. Pregnancy is not a contraindication to postexposure prophylaxis. Pre-exposure prophylaxis may be indicated during pregnancy if the risk for exposure to rabies is significant (CDC 2011).
Serum rabies antibody titer (if rabies immune globulin is inadvertently administered after the eighth day from the first rabies vaccine dose).
Rabies immune globulin is a solution of globulins dried from the plasma or serum of selected adult human donors who have been immunized with rabies vaccine and have developed high titers of rabies antibody.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
